- Home
- / HCW Biologics
HCW Biologics
Stock Price
$0.4
2024-10-29
Market Capitalization
$16.7 M
2024-10-29
Revenue
$54.2 K
FY, 2025
HCW Biologics Summary
Company Summary
- Overview
- HCW Biologics is a company developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell reduction. It focuses on treatments of cancer, inflamm-aging, and aging-associated diseases. The company aims to offer product candidates to address inflammasomes and senescence simultaneously.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Miramar, FL, US | view all locations
- Website
- https://hcwbiologics.com/
- Cybersecurity rating
Table of Contents
Key People
Peter Rhode, Chief Scientific Officer, Vice President of Clinical Operations
Rebecca Byam, Chief Financial Officer
LocationsView all
1 location detected
Miramar, FL HQ
United States
2929 N Commerce Pkwy
HCW Biologics Financials
Summary Financials
- Revenue (FY, 2025)
- $54.2K
- Gross profit (FY, 2025)
- $10.8K
- Net income (FY, 2025)
- ($8.0M)
- Cash (FY, 2025)
- $2.0M
- EBIT (FY, 2025)
- ($13.2M)
- Enterprise value
- $21.5M